Tuberculosis (TB), caused by Mycobacterium tuberculosis remains a clinical and public health challenge in Nigeria. This study was carried out to determine the prevalence of M. tuberculosis and rifampicin resistance in patients from five selected health facilities in Nasarawa State, Nigeria. The HIV serostatus and the CD4+ count of seropositive individuals were also determined. Using a combination of Zhiel Neelsen staining and WHO approved GeneXpert MTB/Rif device for M. tuberculosis and rifampicin resistance, the presence of M. tuberculosis in sputum samples was detected and confirmed. A total of 346 samples were analysed, out of which M. tuberculosis was detected in 91 (26.3%) samples and rifampicin resistance in 6 (6.6%) of the positive samples. HIV prevalence was found to be 46.8%, HIV and TB co-infection 39.6%, while 83.3% of the rifampicin resistance was from HIV positive cases. Tuberculosis was found to be decreasing with increase in CD4 count. Statistically, there was a significant relationship (P < 0.05), between level of education, HIV, CD4 count and TB occurrence. However, no significant relationship (P > 0.05) between gender, occupation and age with TB was observed. Our results show that tuberculosis still remains endemic in Nasarawa state with a high prevalence of HIV and that the confluence of HIV and tuberculosis increased the rate of rifampicin resistance. Provision of Tuberculosis diagnostics with the capacity to detect TB drug resistance beyond rifampicin is highly recommended.
| Published in | Science Journal of Public Health (Volume 4, Issue 3) |
| DOI | 10.11648/j.sjph.20160403.18 |
| Page(s) | 214-218 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2016. Published by Science Publishing Group |
Tuberculosis, Rifampicin Resistance, GeneXpert MTB/Rif, Human Immunodeficiency Virus, CD4 Count
| [1] | World Health Organization. “Global tuberculosis control”. Surveillance, planning, financing Rep WHO/HTM/TB/2008393geneva: World Health Organization Report, 2013. |
| [2] | World Health Organization (2014). “Global Tuberculosis Report,” 2014. Retrieved from: www.who.org |
| [3] | E. L. Corbett, C. J. Watt, N. Walker, D. Maher, and B. G. Williams, “The growing burden of tuberculosis: global trends and interactions with the HIV epidemic,” Arch. Internal Med, vol. 163, pp. 1009–1021, 2003. |
| [4] | C. C. Dim, and N. R. Dim, “Trends of tuberculosis prevalence and treatment outcome in an under-resourced setting: The case of Enugu state, South East Nigeria,” Nig Med J, vol. 54, pp. 392-397, 2013. |
| [5] | B. N. Joseph, and E. S. Fanisi, “Assessing Treatment outcomes in previously treated Tuberculosis Patient’s in Nasarawa State, Nigeria: Implication for Resistance,” Merit Res J Med Medical Sc, vol. 3, pp. 130-134, 2015. |
| [6] | M. V. Souza, “Tuberculose empacientes HIV-positivos, um grave problema de saúdemundial,ˮ Rev Bras Farm, vol. 87, pp. 42-44, 2006. |
| [7] | K. Ibrahim, O. O. Akanni, and U. J. Ijah, “The prevalence of tuberculosis in HIV patients in Minna metropolis,” Nig J Microbiol, vol. 18, pp. 212-216, 2004. |
| [8] | S. D. Gyar, E. Dauda, and C. R. Reuben, Prevalence of tuberculosis in HIV/AIDS patients in Lafia, central Nigeria. Int J Curr Microbiol Appl Sc, vol. 3, pp. 831-838, 2014. |
| [9] | H. D. N. Nyamogoba, G. Mbuthia, G. Kikuvi, S. Mpoke, and P. G. Waiyaki, “A high tuberculosis and human immunodeficiency virus co-infection rate and clinical significance of non-tuberculous mycobacteria in Western Kenya,” Afr J Health Sc, Vol. 21, pp. 147-154, 2012. |
| [10] | K. R. Steingart, I. Schiller, D. J. Horne, M. Pai, C. C. Boehme, and N. Dendukuri, “Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults,” Cochrane Database of Systematic Reviews, Issue 1, 2014 Art. No.: CD009593. DOI: 10.1002/14651858.CD009593.pub3. |
| [11] | L. Dinic, P. Akande, E. O. Idigbe, A. Ani, D. Onwujekwu, O. Agbaji, M. Akanbi, R. Nwosu, B. Adeniyi, M. Wahab, C. Lekuk, C. Kunle-Ope, N. Nwokoye, and P. Kanki, “Genetic determinants of drug-resistant tuberculosis among HIV-infected patients in Nigeria,” J Clin Microbiol, Vol. 50, pp. 2905-2909, 2012. |
| [12] | A. Otu, V. Umoh, A. Habib, S. Ameh, L. Lawson, and V. Ansa, “Drug Resistance among Pulmonary Tuberculosis Patients in Calabar, Nigeria,” Pulmonary Med 2013, E1-7, 2013. |
| [13] | L. Lawson, A. G. Habib, M. I. Okobi, D. Idiong, I. Olajide, N. Emenyonu, N. Onuoha, L.E. Cuevas, and S.O. Ogiri, “Pilot study on multidrug resistant tuberculosis in Nigeria,” Ann Afr Med, vol. 9, pp. 184-187, 2010. |
| [14] | A. O. Onipede, O. Idigbe, A. K. Ako-Nai, O. Omojola, A. O. Oyelese, A. O. Aboderin, A. O. Komolafe, and S. N. C. Wemambu, “Seroprevalence of HIV antibodies in TB patients in Ile-Ife,” Afr Med J, vol. 76 pp. 127-132, 1999. |
| [15] | Z. Iliyasu, and M. Babashani, “Prevalence and Predictors of TB coinfection Among HIV seropositive patients attending Aminu Kano Teaching Hospital, Northern Nigeria,” J. Epid, vol. 2 pp. 81-87, 2009. |
| [16] | O. J. Daniel, A. A. Salako, F. A. Oluwole, O. K. Alausa, and O. T. Oladepo, “HIV seroprevalence among newly diagnosed adult PTB patients in Sagamu” Nig J Med, vol. 13, pp. 393-397, 2004. |
| [17] | O. J. Daniel, O. B. Ogunfowora, and O. T. Oladapo, “HIV seroprevalence among Children diagnosed with TB in Nigeria,” Trop Doctor, vol. 37, pp. 268-269, 2007. |
| [18] | G. Pennap, S. Makpa, and S. Ogbu, “The Prevalence of HIV/AIDS among Tuberculosis Patients in a Tuberculosis/Leprosy Referral Center in Alushi, Nasarawa State, Nigeria” The Internet J Epid, vol. 8 no.1, 2009. |
| [19] | P. E. Akpaka, M. Tulloch-Reid, A. Justiz-Vaillant, and M. F. Smikle, “Prevalence of human immunodeficiency virus infection in patients with pulmonary tuberculosis at the National Chest Hospital in Jamaica,” Rev Panam Salud Publ, vol. 19, pp. 38–43, 2006. |
| [20] | S. Tadesse, and T. Tadesse, “HIV co-infection among tuberculosis patients in Dabat, northwest Ethiopia,” J Infect Dis Immun, vol. 5, pp. 29-32, 2013. |
| [21] | M. Santos Neto, F. L. Silva, K. R. Sousa, M. Yamamura, M. P. Popolin, and R. Arcêncio, “Clinical and epidemiological profile and prevalence of tuberculosis/HIV co-infection in a regional health district in the state of Maranhão, Brazil,” J. Bras. Pneumol, vol. 38, pp. 724-732, 2012. |
| [22] | R. C. Rajam Mano and G. M. Muhammad, “A Study on HIV co-infection among pulmonary tuberculosis at a private medical college hospital,” Asian Student Med J, vol. 13, pp. 1-11, 2013. |
| [23] | S. Rajasekaran, C. Chandrasekar, A. Mahilmaran, K. Kanakaraj, D. S. Karthikeyan, and J. Suriakumar, “HIV coinfection among multidrug resistant and extensively drug resistant tuberculosis patients-a trend,” J Indian Med Assoc, vol. 107, pp. 281-286, 2009. |
| [24] | K. Begtrup, M. Melbye, R. J. Biggar, J. J. Goedert, K. Knudsen, and P. K. Andersen, “Progression to acquired immunodeficiency syndrome is influenced by CD4 T-lymphocyte count and time since seroconversion,” Am J Epid, vol. 145, pp. 629-635, 1997. |
| [25] | World Health Organization, “Global tuberculosis control” WHO report, 2010. |
| [26] | J. J. Ellner, “Immunoregulation in TB: observation and implications,” Clin Trans Sc, vol. 3, pp. 23-28, 2010. |
APA Style
Egbe Kingsley, Ike Anthony C., Aleruchi Chuku. (2016). Prevalence of Tuberculosis and Rifampicin Resistance Among Patients Seeking Medical Care in Nasarawa State, North Central Nigeria. Science Journal of Public Health, 4(3), 214-218. https://doi.org/10.11648/j.sjph.20160403.18
ACS Style
Egbe Kingsley; Ike Anthony C.; Aleruchi Chuku. Prevalence of Tuberculosis and Rifampicin Resistance Among Patients Seeking Medical Care in Nasarawa State, North Central Nigeria. Sci. J. Public Health 2016, 4(3), 214-218. doi: 10.11648/j.sjph.20160403.18
AMA Style
Egbe Kingsley, Ike Anthony C., Aleruchi Chuku. Prevalence of Tuberculosis and Rifampicin Resistance Among Patients Seeking Medical Care in Nasarawa State, North Central Nigeria. Sci J Public Health. 2016;4(3):214-218. doi: 10.11648/j.sjph.20160403.18
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.sjph.20160403.18,
author = {Egbe Kingsley and Ike Anthony C. and Aleruchi Chuku},
title = {Prevalence of Tuberculosis and Rifampicin Resistance Among Patients Seeking Medical Care in Nasarawa State, North Central Nigeria},
journal = {Science Journal of Public Health},
volume = {4},
number = {3},
pages = {214-218},
doi = {10.11648/j.sjph.20160403.18},
url = {https://doi.org/10.11648/j.sjph.20160403.18},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.sjph.20160403.18},
abstract = {Tuberculosis (TB), caused by Mycobacterium tuberculosis remains a clinical and public health challenge in Nigeria. This study was carried out to determine the prevalence of M. tuberculosis and rifampicin resistance in patients from five selected health facilities in Nasarawa State, Nigeria. The HIV serostatus and the CD4+ count of seropositive individuals were also determined. Using a combination of Zhiel Neelsen staining and WHO approved GeneXpert MTB/Rif device for M. tuberculosis and rifampicin resistance, the presence of M. tuberculosis in sputum samples was detected and confirmed. A total of 346 samples were analysed, out of which M. tuberculosis was detected in 91 (26.3%) samples and rifampicin resistance in 6 (6.6%) of the positive samples. HIV prevalence was found to be 46.8%, HIV and TB co-infection 39.6%, while 83.3% of the rifampicin resistance was from HIV positive cases. Tuberculosis was found to be decreasing with increase in CD4 count. Statistically, there was a significant relationship (P 0.05) between gender, occupation and age with TB was observed. Our results show that tuberculosis still remains endemic in Nasarawa state with a high prevalence of HIV and that the confluence of HIV and tuberculosis increased the rate of rifampicin resistance. Provision of Tuberculosis diagnostics with the capacity to detect TB drug resistance beyond rifampicin is highly recommended.},
year = {2016}
}
TY - JOUR T1 - Prevalence of Tuberculosis and Rifampicin Resistance Among Patients Seeking Medical Care in Nasarawa State, North Central Nigeria AU - Egbe Kingsley AU - Ike Anthony C. AU - Aleruchi Chuku Y1 - 2016/05/13 PY - 2016 N1 - https://doi.org/10.11648/j.sjph.20160403.18 DO - 10.11648/j.sjph.20160403.18 T2 - Science Journal of Public Health JF - Science Journal of Public Health JO - Science Journal of Public Health SP - 214 EP - 218 PB - Science Publishing Group SN - 2328-7950 UR - https://doi.org/10.11648/j.sjph.20160403.18 AB - Tuberculosis (TB), caused by Mycobacterium tuberculosis remains a clinical and public health challenge in Nigeria. This study was carried out to determine the prevalence of M. tuberculosis and rifampicin resistance in patients from five selected health facilities in Nasarawa State, Nigeria. The HIV serostatus and the CD4+ count of seropositive individuals were also determined. Using a combination of Zhiel Neelsen staining and WHO approved GeneXpert MTB/Rif device for M. tuberculosis and rifampicin resistance, the presence of M. tuberculosis in sputum samples was detected and confirmed. A total of 346 samples were analysed, out of which M. tuberculosis was detected in 91 (26.3%) samples and rifampicin resistance in 6 (6.6%) of the positive samples. HIV prevalence was found to be 46.8%, HIV and TB co-infection 39.6%, while 83.3% of the rifampicin resistance was from HIV positive cases. Tuberculosis was found to be decreasing with increase in CD4 count. Statistically, there was a significant relationship (P 0.05) between gender, occupation and age with TB was observed. Our results show that tuberculosis still remains endemic in Nasarawa state with a high prevalence of HIV and that the confluence of HIV and tuberculosis increased the rate of rifampicin resistance. Provision of Tuberculosis diagnostics with the capacity to detect TB drug resistance beyond rifampicin is highly recommended. VL - 4 IS - 3 ER -
Email: